-
Categories
-
Recent Posts
-
Recent Comments
- Joseph Francis on Europe’s Top Regulator Shows His Teeth
- Joseph Francis on Pfizer’s Virtual Trial Recruitment
- Nimer Yusef on Can “Clinical Data Integration on the Cloud” be a Reality?
Tags
CBI China conference CRO/Sponsor CROs data DIA drug development eClinical EDC EMA EU Europe European Medicines Agency facebook FDA IIR India IT JOhn Dalli Kayda Norman Ken Getz Lisa Henderson London oncology Oracle Partnerships in Clinical Trials patient/subject recruitment patients Peter O'Donnell Pfizer Pharmaceutical Executive Pharmaceutical Technology Philip Ward PRO R&D Regulatory REMS Sites social media subject recruitment subjects Tim Denman UK Wayne KubickJoin ACT for discussions, news, and more on
Category Archives: Uncategorized
New Patient Group Gets Muted Response—So Far
It’s probably fair to say that the European Patients’ Academy on Therapeutic Innovation (EUPATI) has made a rather slow start since its launch on February 1. There doesn’t seem to have been a huge blaze of publicity or a massive wave enthusiasm for the new group, which has so far amassed a mere 13 followers [...]
Government Funded Research, Is it That Different?
In December 2011, the President’s Bioethics Commission released its “Moral Science: Protecting Participants in Human Subjects Research.” The report was ordered by President Obama following an October 2010 revelation that the US Public Health Service supported unethical research in Guatemala from 1946 to 1948 that involved intentionally exposing thousands of Guatemalans to sexually transmitted diseases [...]
Posted in Uncategorized Tagged Bioethics Commission, government funded research, Lisa Henderson, NIH, President Obama Leave a comment
Calculating the Cost of R&D: Defending Tufts Research
Estimates of what it takes to deliver a compound to market are more than an academic exercise — such data has an increasingly important on-the-ground impact on industry revenues, because if you cannot justify your costs how do you expect to prevail on price? Fundamental to the debate on the “productivity lag” in drug R&D [...]
Your Help Needed on Survey
This survey https://www.surveymonkey.com/s/96RD6CH will close on Friday, so this is your chance to share your views on Clinical Trial Agreements.
It is widely known that the site agreement negotiations of Clinical Trial Agreements are a delaying factor in clinical trial start-ups. Applied Clinical Trials and Salvius Legal BV are collaborating on a survey https://www.surveymonkey.com/s/96RD6CH to obtain [...]
BMJ Wages War on Missing Trial Data
The editors of the British Medical Journal have certainly started the New Year in a determined and resolute mood. They’ve published a special issue this week about missing data in clinical research, arguing that this problem distorts the scientific record to the extent that clinical decisions cannot be based on the best evidence.
This is not [...]
Posted in Uncategorized Tagged Beth Hart, BMJ, British Medial Journal, data, Elizabeth Loder, Joseph S. Ross, Philip Ward, Richard Lehman Leave a comment
2012: Hot Topics
There are predictions, resolutions, and lists that fill out end of year reading for every industry. I’m hesitant to go out on a limb and make predictions because the future is fickle, and resolutions only work with a firm direction. Neither of these will work for the clinical trials industry this coming year.
But what I [...]
£180 Million Program to Support UK Life Science Businesses
The Prime Minister recently announced some welcome news for the UK’s life science businesses: The Technology Strategy Board, a government body intended to help ensure the United Kingdom is a global leader in innovation, and the Medical Research Council, a government agency that encourages and supports research to improve human health, are managing a three-year [...]
Posted in Uncategorized Tagged Biomedical Catalyst Fund, Medical Research Council, NHS, Technology Strategy Board, UK Leave a comment
Data from Emerging Markets is Questioned
Do clinical trials professionals, the ones that subscribe to our magazine and visit our website, monitor stock prices and the ups and downs of biopharm companies involved in drug development?
I don’t know, if you do, let me know. I don’t get heavily into finances, but I do occasionally read Adam Feuerstein’s articles on TheStreet.com. He [...]
Posted in Uncategorized Tagged Adam Feuerstein, China, emerging markets, FDA, India, Lisa Henderson, RENAISSANCE, Targacept, thestreet Leave a comment
A New Approach to India and China?
Executives faced with mouth-watering growth rates in the Chinese and Indian pharmaceutical markets—as opposed to broad plateaus in the United States and Europe—should first think about what they have to offer, instead of what they can grab, according to panelists at the Center for Healthcare Innovation’s inaugural symposium.
Scarcity in both countries represents an entrepreneurial advantage, [...]
Posted in Uncategorized Leave a comment
Pfizer’s Proactivity Approach to Birth Control Pill Recall